$CRVO
CervoMed Inc.

2015 Q4 Form 10-K Financial Statement

#000143774917005713 Filed on March 31, 2017

View on sec.gov

Income Statement

Concept 2015 Q4 2015 2014 Q4
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $1.290M $2.520M $1.560M
YoY Change -17.31% -47.06% 437.93%
% of Gross Profit
Research & Development $1.270M $3.875M $1.530M
YoY Change -16.99% 35.47%
% of Gross Profit
Depreciation & Amortization $0.00 $23.27K -$310.0K
YoY Change -100.0% -95.89% -146.97%
% of Gross Profit
Operating Expenses $2.570M $23.83M -$1.200M
YoY Change -314.17% 63.04% -227.66%
Operating Profit -$6.406M
YoY Change -56.16%
Interest Expense -$150.0K $313.1K -$10.00K
YoY Change 1400.0% 14.48% -106.67%
% of Operating Profit
Other Income/Expense, Net $6.357K $530.0K
YoY Change -100.25% 2550.0%
Pretax Income -$2.720M -$6.719M -$7.880M
YoY Change -65.48% -60.87% 910.26%
Income Tax $0.00 -$2.820M
% Of Pretax Income
Net Earnings -$2.720M -$6.719M -$5.070M
YoY Change -46.35% -53.18% 525.93%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share -$10.46M -$39.53M -$36.21M
COMMON SHARES
Basic Shares Outstanding 18.61M 18.61M 18.61M shares
Diluted Shares Outstanding 18.61M

Balance Sheet

Concept 2015 Q4 2015 2014 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $2.000M $2.000M $21.88M
YoY Change -90.86% -90.86% 8652.0%
Cash & Equivalents $1.997M $2.000M $2.337M
Short-Term Investments
Other Short-Term Assets $50.00K $50.00K $2.290M
YoY Change -97.82% -97.82% -16.42%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $2.043M $2.040M $24.17M
YoY Change -91.55% -91.56% 706.16%
LONG-TERM ASSETS
Property, Plant & Equipment $52.00K $50.00K $102.3K
YoY Change -49.18% -50.0% 808.5%
Goodwill $6.900M $12.06M
YoY Change -42.77% 57.74%
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $181.5K $180.0K
YoY Change
Total Long-Term Assets $233.5K $240.0K $18.61M
YoY Change -98.75% -98.71% 21.26%
TOTAL ASSETS
Total Short-Term Assets $2.043M $2.040M $24.17M
Total Long-Term Assets $233.5K $240.0K $18.61M
Total Assets $2.277M $2.280M $42.78M
YoY Change -94.68% -94.67% 133.2%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $424.7K $420.0K $417.3K
YoY Change 1.77% 0.0% -72.55%
Accrued Expenses $620.0K $620.0K $1.920M
YoY Change -67.71% -67.71% -44.83%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $420.0K $420.0K $0.00
YoY Change -100.0%
Total Short-Term Liabilities $1.471M $1.470M $2.339M
YoY Change -37.09% -37.18% -73.66%
LONG-TERM LIABILITIES
Long-Term Debt $820.0K $820.0K $0.00
YoY Change
Other Long-Term Liabilities $28.27K $30.00K
YoY Change
Total Long-Term Liabilities $28.27K $850.0K $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $1.471M $1.470M $2.339M
Total Long-Term Liabilities $28.27K $850.0K $0.00
Total Liabilities $2.318M $2.320M $4.613M
YoY Change -49.75% -49.67% -61.17%
SHAREHOLDERS EQUITY
Retained Earnings -$42.15M -$75.29M
YoY Change -44.01% 23.55%
Common Stock $42.11M $113.5M
YoY Change -62.88% 68.34%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$41.62K -$40.00K $38.17M
YoY Change
Total Liabilities & Shareholders Equity $2.277M $2.280M $42.78M
YoY Change -94.68% -94.67% 133.2%

Cashflow Statement

Concept 2015 Q4 2015 2014 Q4
OPERATING ACTIVITIES
Net Income -$2.720M -$6.719M -$5.070M
YoY Change -46.35% -53.18% 525.93%
Depreciation, Depletion And Amortization $0.00 $23.27K -$310.0K
YoY Change -100.0% -95.89% -146.97%
Cash From Operating Activities -$2.270M -$5.185M -$1.930M
YoY Change 17.62% -42.58%
INVESTING ACTIVITIES
Capital Expenditures -$30.00K $40.29K -$50.00K
YoY Change -40.0% -20.86%
Acquisitions
YoY Change
Other Investing Activities $0.00 $2.500M
YoY Change
Cash From Investing Activities -$30.00K $2.460M -$50.00K
YoY Change -40.0% -4931.39%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $0.00
YoY Change -100.0%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 2.390M 2.386M 80.00K
YoY Change 2887.5% -92.23%
NET CHANGE
Cash From Operating Activities -2.270M -5.185M -1.930M
Cash From Investing Activities -30.00K 2.460M -50.00K
Cash From Financing Activities 2.390M 2.386M 80.00K
Net Change In Cash 90.00K -339.3K -1.900M
YoY Change -104.74% -101.57%
FREE CASH FLOW
Cash From Operating Activities -$2.270M -$5.185M -$1.930M
Capital Expenditures -$30.00K $40.29K -$50.00K
Free Cash Flow -$2.240M -$5.226M -$1.880M
YoY Change 19.15% -42.46%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2016Q4 dffn Accrued Clinical Studies Expenses Current
AccruedClinicalStudiesExpensesCurrent
220978
CY2015Q4 dffn Accrued Clinical Studies Expenses Current
AccruedClinicalStudiesExpensesCurrent
184737
CY2016 dffn Adjustments To Additional Paid In Capital Settlement Of Litigation Issuance Of Convertible Debt
AdjustmentsToAdditionalPaidInCapitalSettlementOfLitigationIssuanceOfConvertibleDebt
2500000
CY2016 dffn Adjustments To Additional Paid In Capital Stock Options Assumed
AdjustmentsToAdditionalPaidInCapitalStockOptionsAssumed
1321000
CY2016 dffn Adjustments To Additional Paid In Capital Stock Warrants Assumed
AdjustmentsToAdditionalPaidInCapitalStockWarrantsAssumed
384000
CY2016Q4 dffn Clinical Studies Deposits Noncurrent
ClinicalStudiesDepositsNoncurrent
CY2015Q4 dffn Clinical Studies Deposits Noncurrent
ClinicalStudiesDepositsNoncurrent
160400
CY2016 dffn Debt Conversion Converted Instrument Related Accrued Interest
DebtConversionConvertedInstrumentRelatedAccruedInterest
16400
CY2015 dffn Debt Conversion Converted Instrument Related Accrued Interest
DebtConversionConvertedInstrumentRelatedAccruedInterest
600000
CY2016Q4 dffn Deferred Tax Assets Capitalized Costs And Other
DeferredTaxAssetsCapitalizedCostsAndOther
4690843
CY2016Q4 dffn Deferred Tax Assets Orphan Drug Credits
DeferredTaxAssetsOrphanDrugCredits
1218069
CY2016 dffn Deferred Tax Assets Valuation Allowance Provision
DeferredTaxAssetsValuationAllowanceProvision
5017047
CY2016 dffn Deferred Tax Assets Valuation Allowance Purchase Accounting
DeferredTaxAssetsValuationAllowancePurchaseAccounting
11159347
CY2016 dffn Depreciation Depletion And Amortization Including Discontinued Operations
DepreciationDepletionAndAmortizationIncludingDiscontinuedOperations
25342
CY2016 dffn Effect Income Tax Rate Reconciliation Litigation Settlement Charge Percent
EffectIncomeTaxRateReconciliationLitigationSettlementChargePercent
0.046
CY2015 dffn Depreciation Depletion And Amortization Including Discontinued Operations
DepreciationDepletionAndAmortizationIncludingDiscontinuedOperations
8268
CY2015 dffn Offering Costs In Accounts Payable
OfferingCostsInAccountsPayable
0
CY2016Q4 dffn Offering Costs Noncurrent
OfferingCostsNoncurrent
180456
CY2015Q4 dffn Offering Costs Noncurrent
OfferingCostsNoncurrent
CY2016 dffn Effective Income Tax Rate Reconciliation Orphan Drug Credits Percent
EffectiveIncomeTaxRateReconciliationOrphanDrugCreditsPercent
0.044
CY2016 dffn Effective Income Tax Rate Reconciliation Severance Costs Percent
EffectiveIncomeTaxRateReconciliationSeveranceCostsPercent
0.028
CY2016 dffn Offering Costs In Accounts Payable
OfferingCostsInAccountsPayable
126110
CY2016Q4 dffn Prepaid Expenses Deposits And Other Assets
PrepaidExpensesDepositsAndOtherAssets
50844
CY2015Q4 dffn Prepaid Expenses Deposits And Other Assets
PrepaidExpensesDepositsAndOtherAssets
45921
CY2016 dffn Proceeds From Reverse Merger Transaction
ProceedsFromReverseMergerTransaction
8500602
CY2015 dffn Proceeds From Reverse Merger Transaction
ProceedsFromReverseMergerTransaction
0
CY2016 dffn Stock Issued During Period Shares Total
StockIssuedDuringPeriodSharesTotal
2226698
CY2016Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1684158
CY2015Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
424675
CY2016Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
72855
CY2015Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
327950
CY2016Q4 us-gaap Accrued Salaries Current
AccruedSalariesCurrent
399740
CY2015Q4 us-gaap Accrued Salaries Current
AccruedSalariesCurrent
56947
CY2016Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
239892
CY2015Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
215029
CY2016Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
69363575
CY2015Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
42102876
CY2015 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
594175
CY2016 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1391068
CY2016 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1391068
CY2015 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
594175
CY2016 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
38446
CY2015 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
165329
CY2016 us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
0
CY2015 us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
147150
CY2016 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
3435243
CY2015 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1938031
CY2016Q4 us-gaap Assets
Assets
17484384
CY2015Q4 us-gaap Assets
Assets
2276596
CY2016Q4 us-gaap Assets Current
AssetsCurrent
1603696
CY2015Q4 us-gaap Assets Current
AssetsCurrent
2043113
CY2016Q4 us-gaap Convertible Debt Noncurrent
ConvertibleDebtNoncurrent
550000
CY2015Q4 us-gaap Convertible Debt Noncurrent
ConvertibleDebtNoncurrent
818646
CY2015Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
1997192
CY2014Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
2336519
CY2016Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
1552852
CY2016 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-444340
CY2015 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-339327
CY2016Q1 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
478200
CY2016Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2015Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2016Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2015Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2016Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
1000000000
CY2015Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
1000000000
CY2016Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
10345637
CY2015Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
8118939
CY2016Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
10345637
CY2015Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
8118939
CY2016Q4 us-gaap Common Stock Value
CommonStockValue
10346
CY2015Q4 us-gaap Common Stock Value
CommonStockValue
8119
CY2016 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-style: italic;">Concentration of Credit Risk </div></div></div> <div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 18.35pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Financial instruments that potentially expose the Company to concentrations of credit risk consist principally of cash on deposit with multiple financial institutions, the balances of which frequently exceed federally insured limits.</div></div></div></div>
CY2016Q4 us-gaap Convertible Debt Current
ConvertibleDebtCurrent
1880000
CY2015Q4 us-gaap Convertible Debt Current
ConvertibleDebtCurrent
424964
CY2015Q4 us-gaap Convertible Long Term Notes Payable
ConvertibleLongTermNotesPayable
818646
CY2016Q4 us-gaap Convertible Notes Payable
ConvertibleNotesPayable
2430000
CY2015Q4 us-gaap Convertible Notes Payable
ConvertibleNotesPayable
1245000
CY2016Q4 us-gaap Convertible Notes Payable Current
ConvertibleNotesPayableCurrent
1880000
CY2015Q4 us-gaap Convertible Notes Payable Current
ConvertibleNotesPayableCurrent
424964
CY2016 us-gaap Debt Conversion Converted Instrument Amount1
DebtConversionConvertedInstrumentAmount1
711495
CY2015 us-gaap Debt Conversion Converted Instrument Amount1
DebtConversionConvertedInstrumentAmount1
19700976
CY2016 us-gaap Debt Conversion Original Debt Amount1
DebtConversionOriginalDebtAmount1
700000
CY2015 us-gaap Debt Conversion Original Debt Amount1
DebtConversionOriginalDebtAmount1
19100000
CY2016Q4 us-gaap Convertible Long Term Notes Payable
ConvertibleLongTermNotesPayable
550000
CY2015Q4 us-gaap Deferred Finance Costs Net
DeferredFinanceCostsNet
1390
CY2016 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-364796
CY2015 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
0
CY2016Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
CY2016Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
7547296
CY2016Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
2720186
CY2015Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
0
CY2016Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
16176394
CY2016Q4 us-gaap Deferred Tax Liabilities
DeferredTaxLiabilities
3279363
CY2016Q4 us-gaap Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets
DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets
3279363
CY2016Q4 us-gaap Deferred Tax Liabilities Noncurrent
DeferredTaxLiabilitiesNoncurrent
3279363
CY2015Q4 us-gaap Deferred Tax Liabilities Noncurrent
DeferredTaxLiabilitiesNoncurrent
CY2016 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
28000
CY2015 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
10000
CY2016 us-gaap Defined Contribution Plan Employer Matching Contribution Percent
DefinedContributionPlanEmployerMatchingContributionPercent
0.04
CY2016 us-gaap Defined Contribution Plan Maximum Annual Contributions Per Employee Percent
DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent
0.9
CY2016 us-gaap Depreciation
Depreciation
25000
CY2015 us-gaap Depreciation
Depreciation
8000
CY2016 us-gaap Depreciation Nonproduction
DepreciationNonproduction
25342
CY2015 us-gaap Depreciation Nonproduction
DepreciationNonproduction
8268
CY2016 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.76
CY2015 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-2.56
CY2016 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
-0.02
CY2016 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.34
CY2016 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
0.272
CY2016 us-gaap Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate
EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
0.042
CY2016 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
-0.001
CY2016 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.023
CY2016 us-gaap Fair Value Of Assets Acquired
FairValueOfAssetsAcquired
21261000
CY2015 us-gaap Fair Value Of Assets Acquired
FairValueOfAssetsAcquired
0
CY2016Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
8639000
CY2015Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
CY2016 us-gaap Gain Loss On Disposition Of Assets1
GainLossOnDispositionOfAssets1
-6761
CY2015 us-gaap Gain Loss On Disposition Of Assets1
GainLossOnDispositionOfAssets1
-1127
CY2016 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
11094146
CY2015 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2522370
CY2015Q4 us-gaap Goodwill
Goodwill
CY2016Q4 us-gaap Goodwill
Goodwill
6929258
CY2016 us-gaap Goodwill Acquired During Period
GoodwillAcquiredDuringPeriod
6929258
CY2015 us-gaap Impairment Of Long Lived Assets To Be Disposed Of
ImpairmentOfLongLivedAssetsToBeDisposedOf
0
CY2016 us-gaap Impairment Of Long Lived Assets To Be Disposed Of
ImpairmentOfLongLivedAssetsToBeDisposedOf
0
CY2016 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-18401415
CY2015 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-6719222
CY2016 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-364796
CY2015 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
CY2016 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
991625
CY2015 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
647584
CY2016 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-319545
CY2015 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
29739
CY2016 us-gaap Interest Expense
InterestExpense
29686
CY2015 us-gaap Interest Expense
InterestExpense
313117
CY2016Q4 us-gaap Interest Payable Current
InterestPayableCurrent
29359
CY2015Q4 us-gaap Interest Payable Current
InterestPayableCurrent
14009
CY2016 us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
1409363
CY2015 us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
0
CY2016Q4 us-gaap Liabilities
Liabilities
8299700
CY2015Q4 us-gaap Liabilities
Liabilities
2318219
CY2016Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
17484384
CY2015Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
2276596
CY2016Q4 us-gaap Liabilities Current
LiabilitiesCurrent
4438422
CY2015Q4 us-gaap Liabilities Current
LiabilitiesCurrent
1471308
CY2016 us-gaap Litigation Settlement Expense
LitigationSettlementExpense
2500000
CY2015 us-gaap Litigation Settlement Expense
LitigationSettlementExpense
0
CY2016 us-gaap Nature Of Operations
NatureOfOperations
<div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1.</div> Organization and Description of Business </div></div></div> <div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 18.35pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Diffusion Pharmaceuticals Inc. &#x201c;Diffusion&#x201d; or &#x201c;the Company&#x201d; is a clinical-stage specialty pharmaceutical company developing new, small-molecule drugs that help regulate the movement of oxygen into tissue by a novel mechanism of action. The Company&#x2019;s lead product candidate, trans sodium crocetinate (&#x201c;TSC&#x201d;), uses this novel mechanism to re-oxygenate the microenvironment of solid cancerous tumors, thereby enhancing tumor cells&#x2019; response to conventional treatment without additional side effects. TSC has received orphan drug designation for the treatment of glioblastoma multiforme (&#x201c;GBM&#x201d;), and the Company expects to enter a Phase III study in newly diagnosed GBM patients in the next <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">twelve</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(12)</div> months, assuming the availability of financial resources.</div></div> <div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 18.35pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">On <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">15,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2015,</div> the Company&#x2019;s predecessor for accounting purposes, Diffusion Pharmaceuticals LLC (&#x201c;Diffusion LLC&#x201d;) entered into a definitive merger agreement with the Company, then known as &#x201c;RestorGenex Corporation&#x201d; and traded on the over-the-counter stock exchange under the ticker symbol &#x201c;RESX.&#x201d; On <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> January</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">8,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016</div> the Company completed the merger with Diffusion LLC under which a newly formed subsidiary of the Company merged with and into Diffusion LLC in an all-stock transaction, with Diffusion LLC surviving as a wholly-owned subsidiary of the Company. Subsequent to the merger, the Company was renamed &#x201c;Diffusion Pharmaceuticals Inc.&#x201d; and the Company&#x2019;s ticker symbol was changed to &#x201c;DFFN.&#x201d; On <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> November</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">9,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016,</div> the Company&#x2019;s common stock (&#x201c;Common Stock&#x201d;) began trading on the NASDAQ Capital Market. </div></div> <div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 18.35pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">The merger transaction was accounted for as a reverse acquisition under the acquisition method of accounting. Because Diffusion LLC&#x2019;s pre-transaction owners held an <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">84.1%</div> economic and voting interest in the combined company immediately following the closing of the merger, Diffusion LLC is considered to be the acquirer of RestorGenex for accounting purposes (See Note <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">12).</div> For purposes of these notes and the financial statements they accompany, unless the context otherwise requires, the terms &#x201c;Diffusion&#x201d; and &#x201c;the Company&#x201d; refer to Old Diffusion, and the term &#x201c;RestorGenex&#x201d; refers to the Company, in each case, for the periods prior to the merger transaction. </div></div> <div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 18.35pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">The Company&#x2019;s members&#x2019; capital at <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">31,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2015</div> has been recast as common stock and additional paid in capital. On <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> August</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">17,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016,</div> the Company effected a <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1</div>-for-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">10</div> reverse split of its common stock. The accompanying consolidated financial statements and these notes give retroactive effect to this reverse stock split. </div></div> <div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 18.35pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 18.35pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Each outstanding unit of membership interest of Diffusion LLC (the &#x201c;Diffusion Units&#x201d;) was converted into the right to receive <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">0.3652658</div> shares of Common Stock (the &#x201c;Exchange Ratio&#x201d;). Additionally, the right of holders of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$1.1</div> million outstanding convertible notes of Diffusion LLC to convert such notes into Diffusion Units was converted into the right to convert such notes into a number of shares of Common Stock equal to the number of Diffusion Units into which such note would have been convertible under the original terms of the note multiplied by the Exchange Ratio. In addition, all outstanding options to purchase Diffusion Units were assumed by the Company and the right to exercise converted into <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,495,615</div> options to purchase Common Stock on terms substantially identical to those in effect prior to the merger transaction, except for adjustments to the underlying number of shares and the exercise price based on the Exchange Ratio.</div></div></div>
CY2016 us-gaap Operating Income Loss
OperatingIncomeLoss
-18371729
CY2015 us-gaap Operating Income Loss
OperatingIncomeLoss
-6406105
CY2016Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
874264
CY2015Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
621669
CY2016 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
1825654
CY2015 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
2386292
CY2016 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
8498271
CY2015 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
2459709
CY2016 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-10768265
CY2015 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-5185328
CY2016 us-gaap Net Income Loss
NetIncomeLoss
-18036619
CY2015 us-gaap Net Income Loss
NetIncomeLoss
-6719222
CY2016Q4 us-gaap Other Assets Miscellaneous Noncurrent
OtherAssetsMiscellaneousNoncurrent
52219
CY2015Q4 us-gaap Other Assets Miscellaneous Noncurrent
OtherAssetsMiscellaneousNoncurrent
21087
CY2016Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
232675
CY2015Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
181487
CY2016Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
31915
CY2015Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
28265
CY2016Q4 us-gaap Other Sundry Liabilities Current
OtherSundryLiabilitiesCurrent
151332
CY2015Q4 us-gaap Other Sundry Liabilities Current
OtherSundryLiabilitiesCurrent
38026
CY2016 us-gaap Payments Of Financing Costs
PaymentsOfFinancingCosts
54346
CY2015 us-gaap Payments Of Financing Costs
PaymentsOfFinancingCosts
15310
CY2016 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
2331
CY2015 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
40291
CY2016 us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
1880000
CY2015 us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
2401602
CY2016 us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
0
CY2015 us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
2500000
CY2016Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
319647
CY2015Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
267025
CY2016Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
79755
CY2015Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
51996
CY2016 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
7252241
CY2015 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3875467
CY2016 us-gaap Research And Development In Process
ResearchAndDevelopmentInProcess
951000
CY2015 us-gaap Research And Development In Process
ResearchAndDevelopmentInProcess
0
CY2016Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-60189237
CY2015Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-42152618
CY2016 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2015 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2016Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
301156
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
1446121
CY2016Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
40.13
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
9.36
CY2016 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
48190
CY2016 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
458828
CY2016 us-gaap Share Based Compensation
ShareBasedCompensation
1391068
CY2015 us-gaap Share Based Compensation
ShareBasedCompensation
594175
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
94599
CY2015Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1495615
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
2207409
CY2015Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
3.92
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
8.09
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
94599
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
2203011
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
8.09
CY2016 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
61.30
CY2016 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
6.25
CY2015 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y277D
CY2016Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
94599
CY2016 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P7Y
CY2016 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y292D
CY2016 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P7Y292D
CY2016 us-gaap Stock Issued During Period Shares Acquisitions
StockIssuedDuringPeriodSharesAcquisitions
1861503
CY2016 us-gaap Stock Issued During Period Shares Conversion Of Convertible Securities
StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
217122
CY2016 us-gaap Stock Issued During Period Shares Issued For Services
StockIssuedDuringPeriodSharesIssuedForServices
45643
CY2016 us-gaap Stock Issued During Period Value Acquisitions
StockIssuedDuringPeriodValueAcquisitions
19546000
CY2015 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
19700976
CY2016 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
711495
CY2016 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
1409363
CY2016Q4 us-gaap Stockholders Equity
StockholdersEquity
9184684
CY2015Q4 us-gaap Stockholders Equity
StockholdersEquity
-41623
CY2014Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-13617552
CY2015Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-41623
CY2016Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
9184684
CY2016 us-gaap Use Of Estimates
UseOfEstimates
<div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-style: italic;">Use of Estimates </div></div></div> <div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 18.35pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">The preparation of financial statements in conformity with US GAAP requires the Company to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. </div></div> <div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 18.35pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">On an ongoing basis, the Company evaluates its estimates using historical experience and other factors, including the current economic environment. Significant items subject to such estimates are assumptions used for purposes of determining stock-based compensation, the fair value of the convertible notes, allocation of the purchase price and accounting for research and development activities. Management believes its estimates to be reasonable under the circumstances. Actual results could differ significantly from those estimates.</div></div></div></div>
CY2016 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
10232791
CY2015 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
2619945

Files In Submission

Name View Source Status
0001437749-17-005713-index-headers.html Edgar Link pending
0001437749-17-005713-index.html Edgar Link pending
0001437749-17-005713.txt Edgar Link pending
0001437749-17-005713-xbrl.zip Edgar Link pending
chart.jpg Edgar Link pending
dffn-20161231.xml Edgar Link completed
dffn-20161231.xsd Edgar Link pending
dffn-20161231_cal.xml Edgar Link unprocessable
dffn-20161231_def.xml Edgar Link unprocessable
dffn-20161231_lab.xml Edgar Link unprocessable
dffn-20161231_pre.xml Edgar Link unprocessable
dffn20161231_10k.htm Edgar Link pending
dffn20161231_10kimg007.jpg Edgar Link pending
dffn20161231_10kimg008.jpg Edgar Link pending
dffn20161231_10kimg009.gif Edgar Link pending
dffn20161231_10kimg011.jpg Edgar Link pending
ex10-17.htm Edgar Link pending
ex10-5.htm Edgar Link pending
ex21-1.htm Edgar Link pending
ex23-1.htm Edgar Link pending
ex3-1.htm Edgar Link pending
ex31-1.htm Edgar Link pending
ex31-2.htm Edgar Link pending
ex32-1.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending